Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Nov
08
Today In Oncology
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo